Share this article
Share this article
LAS VEGAS, Jan. 18, 2021 /PRNewswire/ The surge in the Amyotrophic Lateral Sclerosis (ALS) market can be attributed to a vast pipeline, initiation of HEALEY ALS platform trials, mutation-specific treatment development in the pipeline, a need for a curative treatment option, increase in the ALS prevalence, effective drug approvals in the past 3-4 years, improvisations in market regulatory guidelines, growing awareness about the disease, along with geographical expansions and meaningful collaborations in the ALS pharma industry.
Amyotrophic Lateral Sclerosis Market report offers detailed coverage of the disease, its available treatment options, patient pool, and diagnostic modalities. The report lays down the comprehensive insights into market outlook, upcoming pipeline therapies, and unmet needs along with the major collaboration and funding opportunities in the ALS market landscape.
Share this article
Share this article
JERSEY CITY, N.J., Jan. 14, 2021 /PRNewswire/ Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support for eligible patients with amyotrophic lateral sclerosis (ALS) treated with RADICAVA
® (edaravone) through more efficient communication and exchange of information, including a new hybrid card that can be used to help access appropriate pharmacy and medical co-pay assistance. Our modified all-in-one out-of-pocket assistance program was designed with our patients in mind, to continue to support appropriate, affordable access to treatment with RADICAVA, for eligible patients, said Kevin O Brien, Vice President of Market Access, MTPA. We changed the program processes for handling pharmacy and medical benefit claims to allow patients to use one card, on-the-spot. In addition, we have modified logistical procedures related to co-pay issues fo
Press release content from Accesswire. The AP news staff was not involved in its creation.
Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis
January 8, 2021 GMT
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses this serious debilitating condition.
EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythro
Cinergen: Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses this serious debilitating condition.
EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythrocytes, plasma, skin and liver. The accumulated PPIX is activated by sun exposure, thus generating free